Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, various Asian regions, and both South and Central America, primarily serving cancer centers and hospitals. The company is also engaged in a research collaboration agreement with the National University Hospital in Singapore, working towards the development of a portable cooling and compression device. Established in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.
Target Price
The average target price of PAX.ST is 94.2 and suggests 57.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in